ENGLISH
KOREAN
Company Overview
Business Portfolio
Research & Development
Investment Information
CEO Message
Vision
History
Overseas Corporations
Affiliated Companies
Business Overview
Cord Blood Banking Business
Bio Insurance Business
CHAUM Business(Non-medical)
IT Business
Other Business
CHA Biotech R&D Center
R&D Pipeline
Current Status of Clinical Trials
Patent Grants (Korea/Overseas)
Scientific Publications
IR Presentations
Research & Development
Research & Development
Current Status of Clinical Trials
Type
Cell type
Product
Indication
predecessor award
Phase I clinical trial
Phase II clinical trial
Clinical III Award
Applied technology
Autologous
Immunocytes
CBT101*
solid cancer (Recurrent Glioblastoma )
NK-FF
Allogenic
Immunocytes
Allo-NK
solid cancer
NK-AFF
Neuropathic cells
FMD-NPC
Parkinson’s Disease (PD)
EP-NPC
Stem cell
CordSTEM-DD
Disk Degeneration
MSC-CORD
CordSTEM-ST
Stroke
CordSTEM-AS
Asherman's syndrome
CordSTEM-ARDS
Severe respiratory disease
ES-MSC
premature ovarian failure
H-ES
hESC-RPE
Macular Degeneration (AMD)
Astellas(US)Partnership
hESC-RPE
Stargard's disease
*U.S. FDA designates rare drug for recurrent malignant neuropods (2020.9)
CHA Biotech program
Partnered program
CEO Message
Vision
History
Overseas Corporations
Affiliated Companies
Business Overview
Cord Blood Banking Business
Bio Insurance Business
CHAUM Business(Non-medical)
IT Business
Other Business
CHA Biotech R&D Center
R&D Pipeline
Current Status of Clinical Trials
Patent Grants (Korea/Overseas)
Scientific Publications
IR Presentations
CHA GROUP SITE
CHA Biomedical Group
CHA Cares
CHA-Meditech
CHA Bio F&C
Seoul CRO
Solidus Investment
CHA Vaccine Institute
CMG Pharmaceutical
CHA Healthcare
Cord Blood Bank iCord
Stem Cell Bank Bio Insurance
Paramedic
Chaum
Chaum CHA Biotech